Table 1.
Characteristics of Participants by HIV Serostatus and Abdominal Fat Volume.
| HIV-uninfected | HIV-infected | All Participants | Effect Size1 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VAT | Normal | Elevated2 | All | Normal | Elevated | All | Normal | Elevated | HIV | VAT | VAT HIV-uninfected |
VAT HIV-infected |
| Measure3 | ||||||||||||
| Participant number | 33 | 52 | 85 | 38 | 102 | 140 | 71 | 154 | ||||
| Age (years) | 56.6 (5.7) | 57.7 (5.4) | 57.3 (5.5) | 54.1 (3.4) | 55.8 (4.5) | 55.3 (4.3) | 55.2 (4.7) | 56.4 (4.9) | −0.20* | 0.12 | 0.10 | 0.18* |
| Education (years) | 16.3 (2.2) | 16.6 (2.6) | 16.5 (2.4) | 14.8 (2.8) | 17.8 (11.8) | 17.0 (10.2) | 15.5 (2.6) | 17.4 (9.7) | 0.03 | 0.11 | 0.07 | 0.13 |
| CESD score | 11.8 (14.0) | 10.2 (12.0) | 10.8 (13.0) | 8.7 (7.5) | 9.9 (11.0) | 9.6 (10.0) | 10.2 (11.0) | 10.0 (11.0) | −0.06 | −0.01 | −0.06 | 0.05 |
| White Race | 70 (23) | 90 (47) | 83 (71) | 42 (16) | 78 (79) | 70 (95) | 55 (39) | 82 (126) | 2.2 (1.2-4.3) | 0.27 (0.15-0.50) | 0.25 (0.08-0.80) | 0.21 (0.01-0.47) |
| Enrollment Cohort 1 | 70 (23) | 79 (41) | 76 (65) | 47 (18) | 72 (73) | 65 (91) | 58 (41) | 74 (114) | 1.70 (0.90-3.00) | 0.48 (0.27-0.87) | 0.62 (0.23-1.70) | 0.36 (0.17-0.77) |
| VAT (cm2) | 62.3 (22) | 207.0 (82) | 151.0 (97) | 59.5 (24) | 212.0 (90) | 171.0 (103) | 60.8 (23) | 211.0 (87) | 0.10 | 0.69* | 0.73* | 0.66* |
| BMI (kg/m2) | 23.9 (3.1) | 27.9 (4.2) | 26.3 (4.3) | 22.5 (2.6) | 26.3 (4.0) | 25.3 (4.0) | 23.2 (2.9) | 26.9 (4.1) | −0.12 | 0.41* | 0.45* | 0.43* |
| Hypertension | 30 (10) | 50 (26) | 42 (36) | 37 (14) | 48 (49) | 45 (63) | 34 (24) | 49 (75) | 1.1 (0.7-2.0) | 1.9 (1.0-3.3) | 2.3 (0.9-5.8) | 1.6 (0.7-3.4) |
| Diabetes | 6 (2) | 17 (9) | 13 (11) | 3 (1) | 20 (20) | 15 (21) | 4 (3) | 19 (29) | 1.2 (0.6-2.6) | 5.3 (1.5-18.0) | 3.2 (0.7-16.0) | 9.0 (1.2-70.0) |
| Adiponectin (ng/mL) | 11155 (6498) | 7489 (3528) | 8912 (5184) | 11509 (7432) | 6889 (4122) | 8143 (5595) | 11345 (6966) | 7092 (3930) | −.07 | −.34* | −.28* | −.37* |
| Interleukin-6 (pg/mL) | 1.52 (1.04) | 1.93 (2.81) | 1.77 (2.29) | 4.11 (5.99) | 2.07 (1.86) | 2.62 (3.59) | 2.91 (4.60) | 2.02 (2.22) | .13* | −.09 | .06 | −.16 |
| Cocaine Use | 21 (7) | 10 (5) | 14 (12) | 40 (15) | 27 (27) | 30 (42) | 31 (22) | 21 (32) | 2.7 (1.3-5.4) | 0.6 (0.3-1.1) | 0.4 (0.1-1.4) | 0.6 (0.3-1.2) |
| Stimulant Use | 6 (2) | 4 (2) | 5 (4) | 8 (3) | 14 (14) | 12 (17) | 7 (5) | 11 (16) | 2.9 (0.9-8.8) | 1.5 (0.5-4.4) | 0.6 (0.1-4.6) | 1.9 (0.5-6.9) |
| Current CD4+ T Lymphocyte Count (cells/μL) | n/a | n/a | n/a | 518 (250) | 620 (259) | 292 (260) | n/a | n/a | n/a | n/a | n/a | 0.18* |
| Nadir CD4+ T Lymphocyte Count(cells/μL) | n/a | n/a | n/a | 238 (135) | 308 (189) | 289 (178) | n/a | n/a | n/a | n/a | n/a | 0.01 |
| HIV-1 RNA <50 copies/mL | n/a | n/a | n/a | 68 (26) | 88 (90) | 83 (116) | n/a | n/a | n/a | n/a | n/a | 0.29* (0.12-0.72) |
| AIDS Diagnosis | n/a | n/a | n/a | 24 (9) | 13 (13) | 16 (22) | n/a | n/a | 0.6 (0.5-0.7) | 0.6 (0.3-1.6) | n/a | 0.5 (0.2-1.2) |
1
Point biserial correlation or relative risk (95% Confidence Interval)
2
≥100cm2
3
Mean (standard deviation) or percent (N)
*
p≤0.05; VAT=Visceral Adipose Tissue, CESD=Center for Epidemiological Studies Depression, BMI=Body Mass Index, BP=Blood Pressure